

Nikolaus R Mcfarland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6558662/publications.pdf>

Version: 2024-02-01

79
papers

5,807
citations

145106

33
h-index

87275

74
g-index

79
all docs

79
docs citations

79
times ranked

8369
citing authors

#	ARTICLE	IF	CITATIONS
1	Diffusion Magnetic Resonance Imaging Detects Progression in <scp>Parkinson's</scp> Disease: A Placeboâ€Controlled Trial of Rasagiline. <i>Movement Disorders</i> , 2022, 37, 325-333.	2.2	7
2	Development and Validation of Automated <scp>Magnetic Resonance</scp> Parkinsonism Index 2.0 to Distinguish <scp>Progressive Supranuclear Palsyâ€Parkinsonism</scp> From <scp>Parkinson's Disease</scp>. <i>Movement Disorders</i> , 2022, 37, 1272-1281.	2.2	17
3	Advanced diffusion imaging to track progression in Parkinsonâ€™s disease, multiple system atrophy, and progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2022, 34, 103022.	1.4	12
4	A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study. <i>Movement Disorders</i> , 2021, 36, 681-689.	2.2	22
5	Statistically Defined Parkinsonâ€™s Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons. <i>Journal of Parkinson's Disease</i> , 2021, 11, 283-297.	1.5	8
6	Safety and efficacy of tilvonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 182-192.	4.9	74
7	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021, 7, 16.	2.5	10
8	Robust Î±-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 80.	2.4	11
9	Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care. <i>Frontiers in Neurology</i> , 2021, 12, 694872.	1.1	29
10	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
11	Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence. <i>Journal of the Neurological Sciences</i> , 2020, 408, 116523.	0.3	33
12	Earlyâ€Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease. <i>Movement Disorders</i> , 2020, 35, 781-788.	2.2	12
13	Current Management and Emerging Therapies in Multiple System Atrophy. <i>Neurotherapeutics</i> , 2020, 17, 1582-1602.	2.1	11
14	Introducing a Supportive Care Team for Advance Directive Education in a Neurological and Neurosurgical Patient Population. <i>Journal of Patient Experience</i> , 2020, 7, 1286-1293.	0.4	2
15	Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study. <i>Movement Disorders</i> , 2020, 35, 976-983.	2.2	38
16	Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1388-1395.	2.2	15
17	Neurite orientation dispersion and density imaging (NODDI) and freeâ€water imaging in Parkinsonism. <i>Human Brain Mapping</i> , 2019, 40, 5094-5107.	1.9	71
18	Development of a transcallosal tractography template and its application to dementia. <i>NeuroImage</i> , 2019, 200, 302-312.	2.1	28

#	ARTICLE	IF	CITATIONS
19	A turn for the worse: Turning performance in Parkinson's disease and Essential tremor. <i>Clinical Biomechanics</i> , 2019, 70, 245-248.	0.5	6
20	Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. <i>The Lancet Digital Health</i> , 2019, 1, e222-e231.	5.9	73
21	Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. <i>Lancet Neurology</i> , The, 2019, 18, 549-558.	4.9	108
22	Dissecting α -synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis. <i>Laboratory Investigation</i> , 2019, 99, 982-992.	1.7	15
23	Recognizing and treating atypical Parkinson disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019, 167, 301-320.	1.0	10
24	Depressive Symptoms are Frequent in Atypical Parkinsonian Disorders. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 191-197.	0.8	24
25	Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches. <i>Seminars in Neurology</i> , 2017, 37, 215-227.	0.5	30
26	A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. <i>Neurology</i> , 2017, 88, 152-159.	1.5	104
27	Parkinson Disease and Autoimmune Disorders" What Can We Learn From Genome-wide Pleiotropy?. <i>JAMA Neurology</i> , 2017, 74, 769.	4.5	2
28	Functional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms. <i>Human Brain Mapping</i> , 2017, 38, 4563-4573.	1.9	49
29	Progression marker of Parkinson's disease: a 4-year multi-site imaging study. <i>Brain</i> , 2017, 140, 2183-2192.	3.7	139
30	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017, 32, 1457-1464.	2.2	60
31	Striatal and Hippocampal Atrophy in Idiopathic Parkinson's Disease Patients without Dementia: A Morphometric Analysis. <i>Frontiers in Neurology</i> , 2017, 8, 139.	1.1	32
32	The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome. <i>PLoS ONE</i> , 2017, 12, e0184262.	1.1	15
33	The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, S10-S11.	0.6	0
34	Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes. <i>Neurology</i> , 2016, 87, 709-717.	1.5	45
35	Free water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. <i>Human Brain Mapping</i> , 2016, 37, 2894-2903.	1.9	31
36	The relationship between balance confidence and control in individuals with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 24-28.	1.1	22

#	ARTICLE	IF	CITATIONS
37	Free-water imaging in Parkinson's disease and atypical parkinsonism. <i>Brain</i> , 2016, 139, 495-508.	3.7	165
38	Diagnostic Approach to Atypical Parkinsonian Syndromes. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 1117-1142.	0.4	60
39	Viral expression of ALS-linked ubiquilin-2 mutants causes inclusion pathology and behavioral deficits in mice. <i>Molecular Neurodegeneration</i> , 2015, 10, 25.	4.4	47
40	Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1248-1258.	2.2	52
41	Weight Loss and Impact on Quality of Life in Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0124541.	1.1	54
42	Unexpected Dual Task Benefits on Cycling in Parkinson Disease and Healthy Adults: A Neuro-Behavioral Model. <i>PLoS ONE</i> , 2015, 10, e0125470.	1.1	20
43	Discriminating features of gait performance in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 888-893.	1.1	21
44	The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, S21-S22.	0.6	0
45	Repetitive finger movement performance differs among Parkinson's disease, Progressive Supranuclear Palsy, and spinocerebellar ataxia. <i>Journal of Clinical Movement Disorders</i> , 2015, 2, 6.	2.2	7
46	Global attentional neglect of segmented lines in Parkinson's disease. <i>Neurocase</i> , 2015, 21, 501-508.	0.2	5
47	Abnormal tactile pressure perception in Parkinson's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 808-815.	0.8	3
48	Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. <i>Human Brain Mapping</i> , 2015, 36, 1165-1179.	1.9	51
49	Chronic Treatment with Novel Small Molecule Hsp90 Inhibitors Rescues Striatal Dopamine Levels but Not α -Synuclein-Induced Neuronal Cell Loss. <i>PLoS ONE</i> , 2014, 9, e86048.	1.1	35
50	Driving Errors in Parkinson's Disease: Moving Closer to Predicting On-Road Outcomes. <i>American Journal of Occupational Therapy</i> , 2014, 68, 77-85.	0.1	27
51	Defining the Clinically Meaningful Difference in Gait Speed in Persons With Parkinson Disease. <i>Journal of Neurologic Physical Therapy</i> , 2014, 38, 233-238.	0.7	113
52	MRI Reveals Brain Abnormalities in Drug-Naive Parkinson's Disease. <i>Exercise and Sport Sciences Reviews</i> , 2014, 42, 12-22.	1.6	13
53	The Exam Starts in the Hallway: Movement Disorders in Geriatric Psychiatry. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, S32-S33.	0.6	0
54	An Eight-Year Clinic Experience with Clozapine Use in a Parkinson's Disease Clinic Setting. <i>PLoS ONE</i> , 2014, 9, e91545.	1.1	41

#	ARTICLE	IF	CITATIONS
55	The "Brittle Response" to Parkinson's Disease Medications: Characterization and Response to Deep Brain Stimulation. PLoS ONE, 2014, 9, e94856.	1.1	19
56	Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomedical Chromatography, 2013, 27, 122-129.	0.8	22
57	Variability in clinical phenotypes of heterozygous and homozygous cases of Parkin-related Parkinson's disease. International Journal of Neuroscience, 2013, 123, 847-849.	0.8	4
58	Postural/Gait and Cognitive Function as Predictors of Driving Performance in Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 153-160.	1.5	14
59	Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathologica Communications, 2013, 1, 6.	2.4	49
60	Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. Journal of Neurology, 2013, 260, 521-527.	1.8	33
61	Advancing research towards novel therapeutic approaches. Nature Reviews Neurology, 2013, 9, 70-71.	4.9	0
62	Anti-Tau Antibodies: Hitting the Target. Neuron, 2013, 80, 254-256.	3.8	16
63	Driving Performance and Behaviors: A Comparison of Gender Differences in Parkinson's Disease. Traffic Injury Prevention, 2013, 14, 340-345.	0.6	13
64	Postmortem Brain Levels of Urate and Precursors in Parkinson's Disease and Related Disorders. Neurodegenerative Diseases, 2013, 12, 189-198.	0.8	57
65	Deep brain stimulation response in pathologically confirmed cases of multiple system atrophy. Parkinsonism and Related Disorders, 2012, 18, 86-88.	1.1	16
66	Are Selective Serotonin Reuptake Inhibitors Associated With Greater Apathy in Parkinson's Disease?. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 326-330.	0.9	54
67	Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains. Brain Research, 2012, 1464, 61-72.	1.1	34
68	Interferon- β induces progressive nigrostriatal degeneration and basal ganglia calcification. Nature Neuroscience, 2011, 14, 694-696.	7.1	67
69	Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. Journal of Neurochemistry, 2009, 109, 838-845.	2.1	91
70	β -Synuclein S129 Phosphorylation Mutants Do Not Alter Nigrostriatal Toxicity in a Rat Model of Parkinson Disease. Journal of Neuro pathology and Experimental Neurology, 2009, 68, 515-524.	0.9	111
71	Improvement with corticosteroids and azathioprine in GAD65-associated cerebellar ataxia. Neurology, 2006, 67, 1308-1309.	1.5	17
72	Thalamic Relay Nuclei of the Basal Ganglia Form Both Reciprocal and Nonreciprocal Cortical Connections, Linking Multiple Frontal Cortical Areas. Journal of Neuroscience, 2002, 22, 8117-8132.	1.7	413

#	ARTICLE	IF	CITATIONS
73	The Place of the Thalamus in Frontal Cortical-Basal Ganglia Circuits. <i>Neuroscientist</i> , 2001, 7, 315-324.	2.6	163
74	Organization of thalamostriatal terminals from the ventral motor nuclei in the macaque. <i>Journal of Comparative Neurology</i> , 2001, 429, 321-336.	0.9	94
75	Convergent Inputs from Thalamic Motor Nuclei and Frontal Cortical Areas to the Dorsal Striatum in the Primate. <i>Journal of Neuroscience</i> , 2000, 20, 3798-3813.	1.7	213
76	Striatonigrostriatal Pathways in Primates Form an Ascending Spiral from the Shell to the Dorsolateral Striatum. <i>Journal of Neuroscience</i> , 2000, 20, 2369-2382.	1.7	1,753
77	The Concept of the Ventral Striatum in Nonhuman Primates. <i>Annals of the New York Academy of Sciences</i> , 1999, 877, 33-48.	1.8	210
78	Insular Cortical Projections to Functional Regions of the Striatum Correlate with Cortical Cytoarchitectonic Organization in the Primate. <i>Journal of Neuroscience</i> , 1997, 17, 9686-9705.	1.7	303
79	Organization of thalamic projections to the ventral striatum in the primate. <i>Journal of Comparative Neurology</i> , 1995, 354, 127-149.	0.9	125